Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang: Kanker merupakan masalah kesehatan utama global, dan menjadi penyebab kematian tertinggi kedua. Kemoterapi, sebagai salah satu terapi kanker, efektif meningkatkan kesembuhan dan kualitas hidup pasien, namun memiliki efek samping jangka panjang, termasuk gangguan kognitif. Di Indonesia, belum ada kuesioner khusus untuk menilai gangguan kognitif pada pasien kanker.Tujuan: Penelitian ini bertujuan untuk membuktikan bahwa kuesioner FACT-Cog versi 3 bahasa Indonesia merupakan alat ukur yang valid dan reliabel dalam menilai gangguan kognitif serta dampaknya pada kualitas hidup pasien kanker yang menjalani kemoterapi di Indonesia.Metode: Penelitian ini menggunakan desain potong lintang pada pasien di unit kemoterapi RSCM dari September hingga Oktober 2024. Adaptasi bahasa dan budaya kuesioner FACT-Cog versi 3 dilakukan dengan metodologi translasi bahasa dan trans-budaya berdasarkan kaidah Guillemin dan Beaton. Uji validasi melibatkan 100 subjek, mencakup validasi konstruksi, validasi kriteria, dan uji reliabilitas dengan metode konsistensi internal dan test-retest.Hasil: FACT-Cog versi 3 bahasa Indonesia menunjukkan konsistensi internal tinggi (Cronbach’s α = 0,915) dan test-retest dengan korelasi baik hingga sangat baik (ICC = 0,721-0,976). Validitas konvergen FACT-Cog versi 3 bahasa Indonesia menunjukkan korelasi sedang (r = 0,415-0,606) dengan EORTC QLQ C30 bahasa Indonesia, sementara validasi konstruksi dapat diterima, dengan korelasi dari lemah hingga kuat (r = 0,352-0,889) antara setiap item dengan domain masing-masing. Kesimpulan: Kuesioner FACT-Cog versi 3 bahasa Indonesia merupakan alat ukur yang valid dan reliabel untuk menilai gangguan fungsi kognitif dan dampaknya terhadap kualitas hidup pada pasien kanker dalam terapi kemoterapi di Indonesia.

---

Background: Cancer remain a significant global health concern, ranking as the second leading cause of death worldwide. Chemotherapy, a primary treatment for cancer, has proven effective in enhancing patient recovery and quality of life; however, it is also associated with long-term side effect, including cognitive impairment. In Indonesia, there is currently no specialized tool for assessing cognitive impairment among cancer patients.

Aim: This study aims to validate the Indonesian version of the FACT-Cog version 3 questionnaire as a reliable and valid tool to assess cognitive impairment and its impact on the quality of life in cancer patients undergoing chemotherapy in Indonesia.

Methods: This cross-sectional study was conducted at the chemotherapy units RSCM from September to October 2024. The language and cultural adaptation of the FACT-Cog version 3 questionnaire followed the translation and cross-cultural methodology of Guillemin and Beaton. Validation testing involved 100 subjects, covering construct validation, convergent validation, and reliability testing with internal consistency and test-retest methods.

Results: The Indonesian version of FACT-Cog version 3 demonstrates high internal consistency (Cronbach's α = 0.915) and strong to excellent test-retest reliability (ICC = 0.721-0.976). Convergent validity shows a moderate correlation (r = 0.415-0.606) with the Indonesian version of the EORTC QLQ C30. Construct validity is acceptable, with weak to strong correlations (r = 0.352-0.889) between individual items and their respective domains.

Conclusion: The Indonesian version of FACT-Cog version 3 is a valid and reliable tool to assess cognitive impairment and its impact on the quality of life in cancer patients undergoing chemotherapy in Indonesia."

"Identifikasi IL-6, PCT, dan CRP dalam mendiagnosis awal bakteremia pada pasien leukemia akut dengan demam neutropenia banyak dilakukan. Tujuan studi ini mengetahui performa diagnostik delta IL-6, delta PCT, dan delta CRP sebagai penanda awal kejadian bakteremia pada pasien leukemia akut dewasa dengan neutropenia berat selama menjalani kemoterapi standar (agresif). Desain studi ini potong lintang dengan mengambil semua pasien leukemia akut dewasa yang mengalami neutropenia berat selama menjalani kemoterapi agresif di RS Cipto Mangunkusumo dan RS Kanker Dharmais sejak 9 Agt – 9 Nov 2023. Sampel darah IL-6, PCT dan CRP diambil sebelum mulai kemoterapi dan dalam 24 jam saat mulai mengalami neutropenia berat serta kultur darah aerob volume 40cc dalam 24 jam sejak neutropenia berat. Performa diagnostik delta IL-6, delta PCT, dan delta CRP lemah dan tidak berbeda bermakna sebagai penanda bakteremia dengan AUC 0,6703 (IK95% 0,507-0,833); 0,6821 (IK 95% 0,521-0,844); dan 0,694 (IK 95% 0,532-0,856) serta nilai p=0,9681. Prevalensi bakteremia pada studi ini 64,44% (29/45) dengan bakteri gram positif 77,42% (24/31) dan yang terbanyak ialah Staphylococcus Epidermidis 41,67% (10/24). Walaupun performa diagnostik ketiganya lemah, delta CRP dapat dipertimbangkan digunakan dengan mempertimbangkan biaya dan ketersediaan reagen.

---

IL-6, PCT, and CRP test were often performed in acute leukemia patients with febrile neutropenia as early markers of bacteremia. Our objective was to determine the diagnostic performance of delta IL-6, delta PCT, and delta CRP as early markers of bacteremia in adult acute leukemia patients with severe neutropenia during standard/aggressive chemotherapy. This research was conducted using cross-sectional design by taking all of adult acute leukemia patients with severe neutropenia during aggressive chemotherapy at Cipto Mangunkusumo Hospital and Dharmais Hospital from 9 Aug – 9 Nov 2023. IL-6, PCT and CRP blood samples were taken before starting chemotherapy and within 24 hours of starting to experience severe neutropenia as well as blood cultures aerobic volume 40cc. The diagnostic performance of delta IL-6, delta PCT, and delta CRP were weak and didn’t differ significantly as early markers of bacteremia (p = 0.968) with an AUC of 0.6703 (95% CI 0.507-0.833); 0.6821 (95% CI 0.521-0.844); and 0.694 (95% CI 0.532-0.856). Bacteremia was found in 64.44% (29/45), mostly gram-positive bacteria (77.42%) and Staphylococcus epidermidis 41.67%. Although the diagnostic performance of all three markers were weak, delta CRP can be considered as an early marker regarding the cost and availability of reagents."